

Prof. GÜNGÖR UTKAN

Personal Information

Email: utkan@ankara.edu.tr

Web: <https://avesis.ankara.edu.tr/utkan>

International Researcher IDs

ORCID: 0000-0001-8445-6993

Yoksis Researcher ID: 172746

Education Information

Expertise In Medicine, Ankara University, Ankara Tıp Fakültesi, Ankara Tıp Pr., Turkey 2016 - 2020

Undergraduate, Ankara University, Tıp Fakültesi, Tıp Pr., Turkey 1987 - 1993

Undergraduate, Ankara University, Tıp Fakültesi, Tıp Pr., Turkey 1987 - 1993

Undergraduate, Ankara University, Tıp Fakültesi, Tıp Pr., Turkey 1987 - 1993

Foreign Languages

English, C1 Advanced

Academic Titles / Tasks

Professor, Ankara University, Ankara Tıp Fakültesi, 2012 - Continues

Associate Professor, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2007 - 2012

Advising Theses

UTKAN G., Tanı anında metastatik ve nüks sol kolon ve rektum kanserlerinde setuksimab tedavisinin primer tümörü çıkarılan ve çıkarılmayan hastalarda etkinliğinin karşılaştırılması, Expertise In Medicine, E.SERTESEN(Student), 2021

UTKAN G., Kolorektal kanserli hastalarda beden kitle indeksi, ras mutasyonu, diabetes mellitus arasındaki ilişki, Expertise In Medicine, M.SÖKMEN(Student), 2021

UTKAN G., Setuksimab tedavisi alan kolorektal kanser hastalarında ortalama trombosit hacmi (MPV), nötrofil lenfosit oranı ve ortalama eritrosit volumü (MCV) parametrelerinin prognostik etkisinin değerlendirilmesi, Expertise In Medicine, M.ÖZEL(Student), 2021

UTKAN G., Rektum kanserlerinde tümör lokalizasyonu ile serum CEA ve CA 19-9 düzeyleri arasında korelasyonun değerlendirilmesi, Expertise In Medicine, F.YILMAZ(Student), 2020

UTKAN G., Metastatik Kolon Kanserinde RAS, RAF Mutasyonu, Tümör Belirteçleri (CEA ve Ca 19-9) ve İlişkilerinin Değerlendirilmesi, Expertise In Medicine, Ö.MURAT(Student), 2020

UTKAN G., Yeni tanı opere meme kanseri hastalarında biyoelektriksel empedans analizi sonuçlarının tümörün prognostik faktörleri ve hasta kan gruplarıyla ilişkisi, Expertise In Medicine, H.ERDAL(Student), 2018

UTKAN G., Sorafenibin hepatoselüler kanserde pd-l1 üzerine etkisi, Postgraduate, B.ŞEN(Student), 2018

UTKAN G., Trastuzumab tedavisi alan her2 pozitif metastatik meme kanseri hastalarında başlangıç anundaki vücut kitle indeksinin ortalama yaşam süresi ve progresyon'a kadar geçen süre üzerindeki etkisi ve diğer prognostik faktörlerle ilişkisi, Expertise In Medicine, A.KÖKEN(Student), 2015

- UTKAN G., Meme kanseri hastalarında vücut kitle indeksinin klinik özellikler ve sağkalım ile ilişkisi, Expertise In Medicine, B.ERDOĞDU(Student), 2015
- UTKAN G., Yeni tanı kanser hastalarında anemi parametrelerinin değerlendirilmesi, Expertise In Medicine, G.KENAR(Student), 2013
- UTKAN G., Meme kanserli hastalarda sezaryen, normal vajinal doğum,laktasyon, gebelik sayılarının prognostik faktörlerle ilişkisinin retrospektif değerlendirilmesi, Expertise In Medicine, S.HANIYE(Student), 2013
- UTKAN G., Trastuzumab ile tedavi edilen meme kanserli hastalarda kardiyotoksisitenin erken belirlenmesinde serum biyobelirteçlerinin rolü, Expertise In Medicine, Y.ÜRÜN(Student), 2012

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Exploring the connection between microsatellite instability and inflammatory indicators in cancers**
Karaoglan B. B., SAVAŞ B., Utkan G., Urun Y.
FUTURE ONCOLOGY, 2024 (SCI-Expanded)
- II. **Distributions and prognostic effects of ABO/Rh blood groups in patients with HER2/neu positive gastric and gastroesophageal junction cancer**
Dogan I., Gurbuz M., Aydin E., Karabulut S., Tastekin D., UTKAN G.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.19, 2023 (SCI-Expanded)
- III. **Short-Course Radiotherapy Followed by Consolidation Chemotherapy Is Safe and Effective in Locally Advanced Rectal Cancer: Comparative Short-term Results of Multicenter Propensity Score Case-Matched Study**
BENLİCE Ç., KOÇ M. A., Gulcu B., BİLGİN İ. A., AKYOL C., BACA B., Ozturk E., Guney Y., UTKAN G., ER Ö., et al.
DISEASES OF THE COLON & RECTUM, vol.66, no.5, pp.681-690, 2023 (SCI-Expanded)
- IV. **Short-Course Radiotherapy Followed by Consolidation Chemotherapy Is Safe and Effective in Locally Advanced Rectal Cancer: Comparative Short-term Results of Multicenter Propensity Score Case-Matched Study**
BENLİCE Ç., KOÇ M. A., Gulcu B., BİLGİN İ. A., AKYOL C., Baca B., Ozturk E., Guney Y., UTKAN G., ER Ö., et al.
DISEASES OF THE COLON & RECTUM, no.5, 2023 (SCI-Expanded)
- V. **The effect of primary tumour resection on patients with synchronous metastatic colorectal cancer treated with cetuximab-containing regimens**
Sertesen E., Yekeduz E., KÖKSOY E. B., ÜRÜN Y., ERKEK A. B., DEMİRCİ S., ÜNAL A. E., UTKAN G.
ANZ JOURNAL OF SURGERY, vol.93, no.4, pp.945-950, 2023 (SCI-Expanded)
- VI. **Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors**
YAZGAN S. C., Yekeduz E., UTKAN G., ÜRÜN Y.
PROSTATE, vol.82, no.15, pp.1456-1461, 2022 (SCI-Expanded)
- VII. **Chronic hyperglycemia based on diabetes is independently associated with decreased survival in patients with advanced cancer treated with immune checkpoint inhibitors**
Yekeduz E., KÖKSOY E. B., YAZGAN S. C., KARATAŞ G., ÇAY ŞENLER F., UTKAN G., AKBULUT H., DEMİRKAZIK A., ÜRÜN Y.
ANTI-CANCER DRUGS, vol.33, no.10, pp.1145-1149, 2022 (SCI-Expanded)
- VIII. **The prognostic role of polypharmacy in metastatic colorectal cancer patients treated with regorafenib**
Yekeduz E., Aktas E. G., KÖKSOY E. B., Dogan N., ÜRÜN Y., UTKAN G.
FUTURE ONCOLOGY, vol.18, pp.1067-1076, 2022 (SCI-Expanded)
- IX. **Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study**
Yekeduz E., Ozbay M. F., Caglayan D., Yildirim A., Erol C., Yildirim H. C., Tunc S., Ozyurt N., Ozdemir F., Sendur M. A. N., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.4, 2022 (SCI-Expanded)

- X. **Key considerations and common adverse events for HIV-positive patients with cancer treated with immune checkpoint inhibitors**
Yekeduz E., UTKAN G., ÜRÜN Y.
FUTURE ONCOLOGY, vol.18, pp.413-416, 2022 (SCI-Expanded)
- XI. **Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: Retrospective real-life data**
Gurbuz M., DOĞAN İ., AKKUŞ E., ERMİŞ H., UTKAN G., Vatansever S., TAŞ F.
Dermatologic Therapy, vol.34, 2021 (SCI-Expanded)
- XII. **Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis**
Bakouny Z., Yekeduz E., Braun D. A., Berchuck J. E., Hirsch L., UTKAN G., Lee Y., Trinh Q., Choueiri T. K., ÜRÜN Y.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.166, 2021 (SCI-Expanded)
- XIII. **Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors**
Yekeduz E., Trapani D., Xu W., de Vries E. G. E., Labaki C., Gyawali B., Gulati S., Nabhan C., UTKAN G., Curigliano G., et al.
INTERNATIONAL JOURNAL OF CANCER, vol.149, no.7, pp.1455-1462, 2021 (SCI-Expanded)
- XIV. **mRNA-based COVID-19 vaccines appear not to increase immune events in cancer patients receiving immune checkpoint inhibitors**
Yekeduz E., Ayasun R., KÖKSOY E. B., UTKAN G., ÜRÜN Y., AKBULUT H.
FUTURE VIROLOGY, vol.16, no.9, pp.583-585, 2021 (SCI-Expanded)
- XV. **Response to letter entitled: Re: A systematic review and meta-analysis: The effect of active cancer treatment on severity of COVID-19**
Yekeduz E., UTKAN G., ÜRÜN Y.
EUROPEAN JOURNAL OF CANCER, vol.152, pp.248-249, 2021 (SCI-Expanded)
- XVI. **In the Age of Immunotherapy, How Can We Translate the CARMENA Results into Practice?**
Yekeduz E., SÜER E., UTKAN G., BALTAÇI S., ÜRÜN Y.
EUROPEAN UROLOGY ONCOLOGY, vol.4, no.3, pp.515-516, 2021 (SCI-Expanded)
- XVII. **Commentary: Should all cancer patients be tested for COVID-19 before each chemotherapy cycle?**
Yekeduz E., UTKAN G., ÜRÜN Y.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.27, no.2, pp.450-452, 2021 (SCI-Expanded)
- XVIII. **Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?**
Yekeduz E., UTKAN G., Kanesvaran R., ÜRÜN Y.
PROSTATE INTERNATIONAL, vol.9, no.1, pp.1-5, 2021 (SCI-Expanded)
- XIX. **A retrospective multicenter study: Clinicopathological factors affecting recurrence-free survival in operable gastric cancer patients.**
Yekeduz E., Dogan I., AKBULUT H., Karabulut S., UTKAN G., ÜRÜN Y.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.3, 2021 (SCI-Expanded)
- XX. **Osteopontin is a Prognostic Factor in Patients with Advanced Gastric Cancer**
YAZICI O., Dogan M., Ozal G., AKTAŞ S. H., Demirkazik A., UTKAN G., ÇAY ŞENLER F., Icli F., AKBULUT H.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, vol.24, no.8, pp.1229-1235, 2021 (SCI-Expanded)
- XXI. **ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis**
Yekeduz E., KÖKSOY E. B., AKBULUT H., ÜRÜN Y., UTKAN G.
FUTURE ONCOLOGY, vol.17, no.03, pp.349-357, 2021 (SCI-Expanded)
- XXII. **Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer**
Kenar G., KÖKSOY E. B., ÜRÜN Y., UTKAN G.
SUPPORTIVE CARE IN CANCER, vol.28, no.11, pp.5235-5242, 2020 (SCI-Expanded)
- XXIII. **Sweet's syndrome under ipilimumab therapy and a brief comparison of the cases in literature**

- Yasar H. A., AKKUŞ E., HEPER A., Akay B. N., ÜRÜN Y., UTKAN G.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.7, pp.1762-1764, 2020 (SCI-Expanded)
- XXIV. **A clinical dilemma amid COVID-19 pandemic: missed or encountered diagnosis of cancer?**
Yekeduz E., Karcioğlu A. M., UTKAN G., ÜRÜN Y.
FUTURE ONCOLOGY, vol.16, no.25, pp.1879-1881, 2020 (SCI-Expanded)
- XXV. **Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab**
Yekeduz E., DURSUN B., Aydin G., YAZGAN S. C., Ozturks H. H., AZAP A., UTKAN G., ÜRÜN Y.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, no.5, pp.1289-1294, 2020 (SCI-Expanded)
- XXVI. **The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer**
Yasar H. A., Yucel K. B., Arslan C., Ucar G., Karakaya S., Bilgin B., Taban H., Kucukarda A., Erturk I., Hizal M., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.5, pp.1110-1116, 2020 (SCI-Expanded)
- XXVII. **A systematic review: Role of systemic therapy on treatment and prevention of brain metastasis in renal cell carcinoma**
Yekeduz E., Arzu Yasar H. A., UTKAN G., ÜRÜN Y.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.4, pp.972-981, 2020 (SCI-Expanded)
- XXVIII. **Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study**
Yasar H. A., Turna H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., Ozdemir N., SENDUR M. A. N., Sezer A., KILIÇKAP S., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.2, pp.267-272, 2020 (SCI-Expanded)
- XXIX. **Prognostic factors for survival in patients with metastatic malignant melanoma treated with ipilimumab: Turkish Oncology Group study**
ÜRÜN Y., Yasar H. A., TURNA Z. H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., Ozdemir N., SENDUR M. A. N., Sezer A., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.25, no.7, pp.1658-1664, 2019 (SCI-Expanded)
- XXX. **Diagnostic serum vitamin D level is not a reliable prognostic factor for resectable breast cancer**
Kaya D. M., Orturk B., Kubilay P., Onur H., UTKAN G., ÇAY ŞENLER F., Alkan A., Yerlikaya H., KÖKSOY E. B., Karci E., et al.
FUTURE ONCOLOGY, vol.14, no.15, pp.1461-1467, 2018 (SCI-Expanded)
- XXXI. **Independent prognostic value of inflammation in metastatic pancreatic cancer.**
Oksuzoglu B., Esin E., Koksoy E. B., Demirci N. S., Sendur M. A. N., Dede I., Sezer A., Karci E., Yildirim N., Yalcin B., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- XXXII. **Comparison of gemcitabine monotherapy with gemcitabine and cisplatin combination in metastatic pancreatic cancer: a retrospective analysis**
Ergun Y., Ozdemir N. Y., Guner E. K., Esin E., SENDUR M. A. N., KÖKSOY E. B., Demirci N. S., Eren T., Dede I., Sezer A., et al.
JOURNAL OF BUON, vol.23, 2018 (SCI-Expanded)
- XXXIII. **Vaccination in oncology practice and predictors**
Alkan A., Karci E., Yasar A., Tuncay G., KÖKSOY E. B., Urun M., ÇAY ŞENLER F., DEMİRKAZIK A., UTKAN G., AKBULUT H., et al.
SUPPORTIVE CARE IN CANCER, vol.25, no.9, pp.2677-2682, 2017 (SCI-Expanded)
- XXXIV. **The significance of serum leptin level in patients with early stage nonsmall cell lung cancer**
Karatas F., YALÇIN B., Sahin S., AKBULUT H., UTKAN G., DEMİRKAZIK A., Icli F.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.13, no.2, pp.204-207, 2017 (SCI-Expanded)
- XXXV. **Widespread Metastatic Prostate Carcinoma Shown by 68Ga-PSMA PET/CT**
SOYDAL Ç., ÖZKAN E., Yerlikaya H., UTKAN G., KÜÇÜK N. Ö.
CLINICAL NUCLEAR MEDICINE, vol.41, no.6, 2016 (SCI-Expanded)
- XXXVI. **Sweet Syndrome After Autologous Stem Cell Transplant**
Alkan A., Idemen C., HEPER A., UTKAN G.

- EXPERIMENTAL AND CLINICAL TRANSPLANTATION, vol.14, no.1, pp.109-111, 2016 (SCI-Expanded)
- XXXVII. **Radiation-Induced Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia**
Alkan A., Kutuk T., Karci E., Yasar A., Hicsonmez A., UTKAN G.
TURKISH JOURNAL OF HEMATOLOGY, vol.33, no.3, pp.248-250, 2016 (SCI-Expanded)
- XXXVIII. **Lung Adenocarcinoma and Synchronous B-Cell Lymphoma of Stomach**
ŞEN E., Yasar A., SAK S., UTKAN G., Erden E., SARYAL S. B.
CHEST, vol.148, no.4, 2015 (SCI-Expanded)
- XXXIX. **The more we use, the more we lose**
Alkan A., Mizrak D., UTKAN G.
MEDICAL ONCOLOGY, vol.32, no.4, 2015 (SCI-Expanded)
- XL. **The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer**
ÜRÜN Y., UTKAN G., Yalcin B., AKBULUT H., Onur H., Oztuna D., Şenler F., DEMİRKAZIK A., Icli F.
Experimental Oncology, vol.37, no.1, pp.53-57, 2015 (SCI-Expanded)
- XLI. **First-Line Crizotinib in ALK-Positive Lung Cancer**
Alkan A., KÖKSOY E. B., UTKAN G.
NEW ENGLAND JOURNAL OF MEDICINE, vol.372, no.8, pp.781-782, 2015 (SCI-Expanded)
- XLII. **Medication errors in chemotherapy preparation and administration: A survey conducted among oncology nurses in Turkey**
Ulas A., Silay K., Akinci S., Dede D. S., AKINCI M. B., ŞENDUR M. A. N., Cubukcu E., COŞKUN H. Ş., Degirmenci M., UTKAN G., et al.
Asian Pacific Journal of Cancer Prevention, vol.16, no.5, pp.1699-1705, 2015 (SCI-Expanded)
- XLIII. **The clinicopathological characteristics with long-term outcomes in malignant mesothelioma**
Dogan M., UTKAN G., Hocazade C., Uncu D., Toptas S., Ozdemir N., Zengin N., Icli F.
MEDICAL ONCOLOGY, vol.31, no.10, 2014 (SCI-Expanded)
- XLIV. **Cetuximab Related Eyelash Elongations for Patients with Metastatic Rectum Carcinoma: Metabolic Complete Response**
ÜRÜN Y., UTKAN G.
ANNALS OF DERMATOLOGY, vol.25, no.4, pp.504-505, 2013 (SCI-Expanded)
- XLV. **Intraabdominal follicular dendritic cell sarcoma: A report of three cases and review of the literature**
ÜRÜN Y., Kankaya D., Koral L., YALÇIN B., Karabork A., CEYHAN K., Boruban M. C., UTKAN G., DEMİRKAZIK A.
Tumori, vol.99, no.2, 2013 (SCI-Expanded)
- XLVI. **Clinicopathological Features of Patients with Malignant Mesothelioma in a Multicenter, Case-Control Study: No Role for ABO-Rh Blood Groups**
UTKAN G., ÜRÜN Y., KAYI CANGIR A., Kilic D., Ozdemir N. Y., Oztuna D., Bulut E., Arslan U. Y., Kocer M., Kavukcu S., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, no.1, pp.249-253, 2013 (SCI-Expanded)
- XLVII. **Isolated Pulmonary Metastasis Presenting with an CEA Elevation Five Years After Radical Prostatectomy**
ÜRÜN Y., UTKAN G., Percinel S., KAYI CANGIR A., Dogani M., Icli F.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.23, no.3, pp.200-201, 2013 (SCI-Expanded)
- XLVIII. **Association of ABO Blood Group and Risk of Lung Cancer in a Multicenter Study in Turkey**
ÜRÜN Y., UTKAN G., KAYI CANGIR A., Oksuzoglu O. B., Ozdemir N., Oztuna D., KOCAMAN G., COŞKUN H. Ş., Kaplan M. A., YÜKSEL C., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, no.5, pp.2801-2803, 2013 (SCI-Expanded)
- XLIX. **Malign peritoneal mesothelioma with nephrotic syndrome**
DOĞAN M. K., Ozal G., SAVAŞ B., Gungor M., UTKAN G., Yalcin B., Icli F.
Bratislava Medical Journal, vol.113, no.1, pp.43-45, 2012 (SCI-Expanded)
- L. **Is obesity always a risk factor for all breast cancer patients? c-erbB2 expression is significantly lower in obese patients with early stage breast cancer**
Mousa U., Onur H., UTKAN G.

- Clinical and Translational Oncology, vol.14, no.12, pp.923-930, 2012 (SCI-Expanded)
- L.I. **Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature**
Dogan M., Yalcin B., Ozdemir N. Y., Arslan U. Y., Dogan L., UTKAN G., AKBULUT H., Zengin N., Alkis N., Icli F.
MEDICAL ONCOLOGY, vol.29, no.3, pp.2021-2026, 2012 (SCI-Expanded)
- L.II. **Primary extranodal non-Hodgkin's lymphoma presenting as painful gingival swelling**
ÜRÜN Y., Can F., BARIŞ E., AKBULUT H., UTKAN G., Icli F.
Experimental Oncology, vol.34, no.2, pp.134-135, 2012 (SCI-Expanded)
- L.III. **ABO and Rh Blood Groups and Risk of Colorectal Adenocarcinoma**
ÜRÜN Y., Ozdemir N. Y., UTKAN G., AKBULUT H., SAVAŞ B., Oksuzoglu B., Oztuna D., DOĞAN İ., YALÇIN B., ÇAY ŞENLER F., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, no.12, pp.6097-6100, 2012 (SCI-Expanded)
- L.IV. **Relationship Between Antimetabolite Toxicity and Pharmacogenetics in Turkish Cancer Patients**
Dogan M., KARABULUT H. G., Tukun A., DEMİRKAZIK A., UTKAN G., Yalcin B., Dincol D., AKBULUT H., Icli F.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.4, pp.1553-1556, 2012 (SCI-Expanded)
- L.V. **Lack of Any Relationship between ABO and Rh Blood Groups and Clinicopathological Features in Patients with Gastrointestinal Stromal Tumors: Turkish Oncology Group**
ÜRÜN Y., Utkan G., YALÇIN Ş., COŞKUN H. Ş., Kocer M., Ozdemir N. Y., Kaplan M. A., Arslan U. Y., ÖZDEMİR F., Oztuna D., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, no.8, pp.4129-4131, 2012 (SCI-Expanded)
- L.VI. **A rare gastric neoplasm: gastric medullary carcinoma**
Dogan M., SAVAŞ B., UTKAN G., BAYAR S., ENSARI A., Icli F.
MEDICAL ONCOLOGY, vol.28, no.4, pp.945-947, 2011 (SCI-Expanded)
- L.VII. **Kikuchi - Fujimoto disease: Cervical lymphadenopathy suggestive of relapsing lymphoma in patient with lymphoblastic lymphoma**
ÜRÜN Y., UTKAN G., Kankaya D., DOĞAN M. K., YALÇIN B., Icli F.
Experimental Oncology, vol.33, no.4, pp.242-244, 2011 (SCI-Expanded)
- L.VIII. **Optimal timing of adjuvant treatment in patients with early breast cancer**
Alkis N., Durnali A. G., Arslan U. Y., Kocer M., Onder F. O., Tokluoglu S., Celenkoglu G., Muallaoglu S., UTKAN G., Ulas A., et al.
Medical Oncology, vol.28, no.4, pp.1255-1259, 2011 (SCI-Expanded)
- L.IX. **Two cases with atypical metastasis in colorectal cancer: Splenic and renal metastasis**
DOĞAN M. K., Ozal G., Ekinci C., UTKAN G., ÜRÜN Y., Yalcin B., Icli F.
Experimental Oncology, vol.32, no.4, pp.277-279, 2010 (SCI-Expanded)
- L.X. **Fifty-one Kaposi sarcoma patients**
Dogan M., Dogan L., ÖZDEMİR F., Ozdemir N. Y., COŞKUN H. Ş., Arslan U. Y., Ozal G., UTKAN G., DEMİRKAZIK A., AYDIN F., et al.
CLINICAL & TRANSLATIONAL ONCOLOGY, vol.12, no.9, pp.629-633, 2010 (SCI-Expanded)
- LXI. **The Prognostic Importance of Leucocytosis, Thrombocytosis and Serum Vascular Endothelial Growth Factor (VEGF) Level in Inoperable Non-Small Cell Lung Cancer (NSCLC): A Match-Pair Analysis**
DEMİRKAZIK A., Asik M., Yalcin B., Dogan M., Buyukcelik A., Sencan O., UTKAN G., AKBULUT H., Icli F.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.20, no.1, pp.14-19, 2010 (SCI-Expanded)
- LXII. **Activity of pemetrexed on brain metastases from non-small cell lung cancer: What is the mechanism?**
Dogan M., Yalcin B., UTKAN G., ÜRÜN Y., Ozal G.
LUNG CANCER, vol.66, no.3, pp.399, 2009 (SCI-Expanded)
- LXIII. **Angiotensin-converting enzyme inhibitors: Do they contribute to delayed chemotherapy induced nausea and vomiting?**
Dogan M., Yalcin B., Ozal F. G., Buyukcelik A., UTKAN G., Icli F., Dogan L.
Medical Hypotheses, vol.73, no.4, pp.628-629, 2009 (SCI-Expanded)
- LXIV. **Low molecular weight heparin (LMWH) increases the efficacy of cisplatin plus gemcitabine combination in advanced pancreatic cancer**

- Icli F., AKBULUT H., Utkan G., Yalcin B., Dincol D., Isikdogan A., DEMİRKAZIK A., Onur H., Cay F., Buyukcelik A.
JOURNAL OF SURGICAL ONCOLOGY, vol.95, no.6, pp.507-512, 2007 (SCI-Expanded)
- LXV. **Alpha fetoprotein producing gastric hepatoid adenocarcinoma**
UTKAN G., Büyükcilik A., CEYHAN K., Ortabozkoyun L., Tek I., Yalçın B., Dinçol D.
Journal of the Pakistan Medical Association, vol.56, no.6, pp.292-293, 2006 (SCI-Expanded)
- LXVI. **An unspecified neurologic paraneoplastic syndrome pointing out an occult relapse of ovarian cancer: A case report**
Büyükcilik A., DEMİRKAZIK A., Yalçın B., Şener Ö., UTKAN G., Tulunay G., Icli F.
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.15, no.4, pp.199-202, 2005 (SCI-Expanded)
- LXVII. **Intracranial aggressive fibromatosis presenting as panhypopituitarism and diabetes insipidus**
Gursoy A., Cesur M., Aktaş B., UTKAN G., Gedik V. T., ERDOĞAN M. F., Kamel N.
Pituitary, vol.8, no.2, pp.123-126, 2005 (SCI-Expanded)
- LXVIII. **Adjuvant Chemotherapy for Lung Cancer [1] (multiple letters)**
Ikhlaque N., Baumann M. A., Büyükcilik A., UTKAN G., Yalçın B., Feliu J., Espinosa E., Javier Sánchez J., Sauter C., Morgan G. W., et al.
New England Journal of Medicine, vol.350, no.16, pp.1681-1683, 2004 (SCI-Expanded)
- LXIX. **The prognostic Importance of Venous Thromboembolism (VT) in cancer patients and its relationship with the ieveis of factor VIII and Vascular Endothelial Growth Factor (VEGF)**
DEMİRKAZIK A., Dogan M., Konuk N., AKBULUT H., Yalcin B., Buyukcelik A., Tek I., UTKAN G., Onur H., Icli F.
ANNALS OF ONCOLOGY, vol.15, pp.151, 2004 (SCI-Expanded)

Articles Published in Other Journals

- I. **Enhancing the Anti-angiogenic Effect of Bevacizumab with ACE Inhibition on mCRC**
ERDAT E. C., KÖKSOY E. B., UTKAN G.
JOURNAL OF GASTROINTESTINAL CANCER, vol.54, no.3, pp.897-902, 2023 (ESCI)
- II. **The relationship between body mass index and clinical properties/survival in patients with breast cancer**
ERDOĞDU B., UTKAN G.
The European Research Journal, vol.9, no.4, pp.770-778, 2023 (Peer-Reviewed Journal)
- III. **Relationship Between ABO Blood Group and Microsatellite Instability in Colorectal Cancer: A Retrospective Single-Center Study**
Karaoglan B. B., AKYOL C., ÜNAL A. E., Kuzu A., SAVAŞ B., UTKAN G.
JOURNAL OF GASTROINTESTINAL CANCER, 2023 (ESCI)
- IV. **Factors affecting survival in locally advanced rectal cancer - Single center experience**
Yasar H. A., Örüncü M. B., UTKAN G., Akbulut H.
Akademik Gastroenteroloji Dergisi, vol.22, no.2, pp.71-76, 2023 (Peer-Reviewed Journal)
- V. **The relation between gastric cancer and ABO blood groups: multicenter, observational, case-control study**
Yasar H. A., UTKAN G., Ozdemir N., oksuzoglu b., DEDE İ., ÜRÜN Y., Akbulut H.
Akademik Gastroenteroloji Dergisi, vol.22, no.2, pp.67-70, 2023 (Peer-Reviewed Journal)
- VI. **Systemic Immune-Inflammation Index as a Prognostic Marker of Late Recurrence in Operable Gastric Cancer: a Dual-Center Study**
Yekeduz E., DOĞAN İ., Kaya D. M., ÖZGÜR İ., UTKAN G., VATANSEVER S., DEMİRCİ S., AKBULUT H., ÜRÜN Y.
JOURNAL OF GASTROINTESTINAL CANCER, vol.53, no.4, pp.870-879, 2022 (ESCI)
- VII. **Predictive Factor for Lymph Node Metastasis in Non-Metastatic Colorectal Adenocarcinomas**
Karci E., Ürün Y., Köksoy E. B., Yekedüz E., Utakan G., Akbulut H., Uçar G., Bilgin B., Arslan Ç., Alkan A., et al.
Eurasian Journal of Medical Investigation, vol.6, no.3, pp.279-283, 2022 (Peer-Reviewed Journal)
- VIII. **Genomic Landscape of Actionable Mutations in Primary and Metastatic Tissues of Colon Adenocarcinoma**

- Yekeduz E., AKBULUT H., UTKAN G., ÜRÜN Y.
CUREUS JOURNAL OF MEDICAL SCIENCE, vol.14, no.4, 2022 (ESCI)
- IX. **Sorafenib in Radioactive Iodine Refractory Differentiated Thyroid Cancer: A Real-life Data with Long-term Experience**
Yekedüz E., Köksoy E. B., Şenler F., Akbulut H., Demirkazık A., Ürün Y., Utkan G.
Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol.75, no.1, pp.103-106, 2022 (Peer-Reviewed Journal)
- X. **The relationship between clinicopathological parameters and PD-L1 expression level in advanced stage non-small cell lung cancer**
Gurbuz M., DOĞAN İ., AKKUŞ E., ÖZAKINCI H., Tolunay P. K., KALACI E., BAĞLAN T., KÖKSOY E. B., CEYHAN K., SAK S., et al.
TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, vol.70, no.2, pp.132-140, 2022 (ESCI)
- XI. **Association between blood type and epidermal growth factor receptor mutation positivity in lung adenocarcinoma patients**
Gürbüz M., AKKUŞ E., Karaalioğlu B., Aktaş E. G., KÖKSOY E. B., ÖZAKINCI H., Hayme S., ÜRÜN Y., SAK S., DEMİRKAZIK A., et al.
Journal of Oncological Science, vol.7, no.1, pp.20-24, 2021 (Scopus)
- XII. **Seasonal influenza and pneumococcal vaccination rates among patients with cancer in covid-19 pandemic: A cross-sectional study**
Yekedüz E., KÖKSOY E. B., YAZGAN S. C., AKBIYIK I., BALLI S., Kavak E. E., KALACI E., DURSUN B., Kubilay Tolunay P., Gürbüz M., et al.
Journal of Oncological Science, vol.7, no.2, pp.64-70, 2021 (Scopus)
- XIII. **Efficacy of Chemotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer Patients - Do Homologous Recombination Deficiency Affect the Outcomes?**
Yekeduz E., UTKAN G., ÜRÜN Y.
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, vol.19, no.4, pp.175-176, 2020 (ESCI)
- XIV. **Intense F-18-Fluorodeoxyglucose Uptake in Brachial Plexus of Patients with Brachial Plexopathy**
Soydal Ç., Gündüz P., Araz M., Utkan G.
MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, vol.29, no.2, pp.79-81, 2020 (ESCI)
- XV. **Intense 18F-Fluorodeoxyglucose Uptake in Brachial Plexus of Patients with Brachial Plexopathy**
SOYDAL Ç., AKKUŞ P., ARAZ M., UTKAN G.
Molecular Imaging and Radionuclide Therapy, vol.29, no.2, pp.79-81, 2020 (ESCI)
- XVI. **The COVID 19 Pandemic and Colorectal Cancer: 5W1H - What Should We Do to Whom, When, Why, Where and How?**
AKYOL C., KOÇ M. A., UTKAN G., YILDIZ F., KUZU M. A.
Turkish Journal of Colorectal Disease, vol.30, pp.67-75, 2020 (Peer-Reviewed Journal)
- XVII. **The Impact of Loneliness and Cancer Diagnosis on Cognitive Impairment in Geriatric Patients**
ALKAN A., ÜRÜN Y., UTKAN G., AKBULUT H., TUNCAY G., ARAS S., VARLI M.
Journal of Oncological Sciences, vol.6, no.2, pp.65-70, 2020 (Peer-Reviewed Journal)
- XVIII. **The Impact of Loneliness and Cancer Diagnosis on Cognitive Impairment in Geriatric Patients.**
ALKAN A., ÖZTORUN H. S., KARCI E., ÜRÜN Y., TUNCAY G., YAŞAR H. A., ÇINAR E., ARAS S., VARLI M., UTKAN G., et al.
Journal of Oncological Sciences, vol.6, no.2, pp.65-70, 2020 (Peer-Reviewed Journal)
- XIX. **Risk factors for thrombosis risk in patients with cancer**
TURAN D., YAŞAR H. A., Aksu O. B., KÖKSOY E. B., UTKAN G., AKBULUT H., ÜRÜN Y.
Journal of Oncological Sciences, vol.4, no.3, pp.130-133, 2018 (Peer-Reviewed Journal)
- XX. **Osteonecrosis of the jaw with sunitinib and zoledronic acid combination: A case report**
Tolunay P. K., YAŞAR H. A., UTKAN G., ÜRÜN Y.
Journal of Oncological Sciences, vol.4, no.2, pp.116-118, 2018 (Peer-Reviewed Journal)
- XXI. **Inadequate Nutritional Status of Hospitalized Cancer Patients**
ALKAN A., MIZRAK KAYA D., ÇAY ŞENLER F., UTKAN G.
Journal of Clinical and Experimental Investigations, vol.8, no.01, pp.12-17, 2017 (Peer-Reviewed Journal)
- XXII. **Oxaliplatin-induced Autoimmune Hemolytic Anemia**

- YAŞAR H. A., ŞAHİN U., SAĞLAM K., ALKAN A., UTKAN G.
 Acta Oncologica Turcica, vol.50, no.2, pp.174-177, 2017 (Peer-Reviewed Journal)
- XXIII. Widespread Metastatic Involvement in a Patient with Merkel Cell Carcinoma on 68Ga-DOTATATE PET/CT: Case Report**
 ÖZKAN E., SOYDAL Ç., ALKAN A., UTKAN G.
 Turkiye Klinikleri Journal of Case Reports, vol.25, no.1, pp.10-13, 2017 (Peer-Reviewed Journal)
- XXIV. Oxaliplatin-induced Autoimmune Hemolytic Anemia**
 YAŞAR H. A., ŞAHİN U., Sağlam K., ALKAN A., UTKAN G.
 ACTA ONCOLOGICA TURCICA, vol.50, no.2, pp.174-177, 2017 (Peer-Reviewed Journal)
- XXV. Porphyria A Rare Cause of Neurological Symptoms in Cancer Patient**
 ALKAN A., karcı E., YAVUZ VEİZİ B. G., Akıncı N., AKDAĞ A., YAŞAR H. A., UTKAN G.
 ACTA ONCOLOGICA TURCICA, vol.49, no.3, pp.251-254, 2016 (Peer-Reviewed Journal)
- XXVI. Osteogenesis Imperfecta, Pseudoachalasia, and Gastric Cancer**
 Mizrak D., Alkan A., Erdogan B., UTKAN G.
 CASE REPORTS IN GASTROINTESTINAL MEDICINE, vol.2015, 2015 (ESCI)
- XXVII. Paraneoplastic digital necrosis associated with rectum carcinoma**
 ALKAN A., ÖZGÜL S., YAŞAR H. A., karcı E., KÖKSOY E. B., UTKAN G.
 Journal of Clinical and Experimental Investigations, vol.6, no.4, pp.391-392, 2015 (Peer-Reviewed Journal)
- XXVIII. Widespread erythematous skin metastasis from breast cancer mimicking generalized drug eruption**
 UTKAN G., Büyükceli A., Okçu A., Avci U., Yalçın B., İçli F.
 Turkish Journal of Cancer, vol.39, no.2, pp.66-68, 2009 (Scopus)
- XXIX. The clinical and pathological features of patients with gastric cancer in Turkey: A Turkish Oncology Group Study**
 Yalçın B., Zengin N., AYDIN F., İlhan M., Işıkdoğan A., Demir G., Aykan F., ÇELİK İ., Dane F., Üstüner Z., et al.
 Turkish Journal of Cancer, vol.36, no.3, pp.108-115, 2006 (Scopus)
- XXX. Frequency of symptoms in patients with advanced cancer**
 Yalçın B., Büyükceli A., Şenler F. Ç., UTKAN G., Tek I., Doğan M., Doruk H., DEMİRKAZIK A., AKBULUT H., İçli F.
 Turkish Journal of Cancer, vol.35, no.4, pp.177-180, 2005 (Scopus)
- XXXI. The opinions of the cancer patients about pain management: A questionnaire study**
 Yalçın B., Şenler F. Ç., Büyükceli A., UTKAN G., Tek I., Doruk H., AKBULUT H., İçli F.
 Turkish Journal of Cancer, vol.34, no.3, pp.114-117, 2004 (Scopus)
- XXXII. Adrenal gland insufficiency in a patient with non-small cell lung cancer: Case report and review of the literature Adrenal gland yetmezliği gelişen bir küçük hücreli dışı akciğer kanseri olusu: Olgu sunumu ve literatürün gözden geçirilmesi**
 Büyükceli A., UTKAN G., DEMİR Ö., Yalçın B., DEMİRKAZIK A., İçli F.
 THOD - Turk Hematoloji-Onkoloji Dergisi, vol.12, no.4, pp.210-214, 2002 (Scopus)

Refereed Congress / Symposium Publications in Proceedings

- I. **GİST HASTALARINDA İMATİNİN ALTINDA KAN LİPİD DÜZEYİ DEĞİŞİKLİKLERİ**
 KÖKSOY E. B., KARCI E., ÜRÜN M., YAŞAR H. A., ÖZYURT N., UTKAN G., AKBULUT H.
 22. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2017, pp.441
- II. **Metastatik kororektal karsinomda TARE etkinliği, tek merkez deneyimi.**
 DURSUN B., DEMİR B., SOYDAL Ç., UTKAN G.
 9.Türk Tibbi Onkoloji Derneği Kongresi, Cyprus (Kktc), 18 May 2022
- III. **Nüks folliküler lenfoma olgusunda prostat tutulumu**
 ÖZYURT N., YAŞAR H. A., GÜRBÜZ M., KUBİLAY TOLUNAY P., YEKİDÜZ E., KARAALİOĞLU B., UTKAN G.
 23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 21 April 2019, pp.442
- IV. **Nazofarenks Kanserli Hastalarda Sağkalım İle İlişkili Prognostik Faktörler**
 YAŞAR H. A., KUBİLAY TOLUNAY P., DEMİRKIRAN A., KARAAĞAÇ M., GÜMÜŞTEPE E., UTKAN G., ARTAŞ M.,

- AKBULUT H.
23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 21 April 2019
- V. **Efficacy of The Second-line Treatment in Metastatic Pancreas Cancer**
ŞENDUR M. A. N., BİLGİN B., KARCI GÜNER E., HIZAL M., ERGÜN Y., ESİN E., KÖKSOY E. B., SEZER A., AKINCI M. B., ÖZDEMİR N., et al.
8th International Gastrointestinal Cancer Conference, İstanbul, Turkey, 7 - 09 December 2018
- VI. **DETERMINATION OF THE PROGNOSTICMARKERS BEFORE SECONDLINE TREATMENT INMETASTATIC PANCREAS CANCER**
BİLGİN B., karcı e., ŞENDUR M. A. N., hizal m., yakup e., esin e., KÖKSOY E. B., AKINCI M. B., SEZER A., ÖZDEMİR N., et al.
8 th INTERNATIONALGASTROINTESTINALCANCER CONFERENCE, 7 - 09 December 2018
- VII. **MIDE KANSERİ VE ABO KAN GRUBU İLİŞKİSİ: ÇOK MERKEZLİ, GÖZLEMSEL, VAKA-KONTROL ÇALIŞMASI**
YAŞAR H. A., UTKAN G., ÖZDEMİR N., ÇAKMAK ÖKSÜZOĞLU Ö. B., DEDE İ., ÜRÜN Y., AKBULUT H.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, pp.443
- VIII. **NADIR BİR VAKA: SEFUROKSİM KULLANIMI SONRASINDA GELİŞEN RADYASYON RECALL DERMATITİ**
YAŞAR H. A., KUBİLAY TOLUNAY P., ÜRÜN Y., UTKAN G.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, pp.282
- IX. **Pankreas Kanseri ve ABO Kan Grubu İlişkisi: Çok Merkezli, Gözlemsel, Vaka-Kontrol Çalışması**
KÖKSOY E. B., UTKAN G., ERGÜN Y., ESİN E., ŞENDUR M. A. N., KARCI GÜNER E., DEDE İ., DEMİRCİ N. S., SEZER A., ENGİN H., et al.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018
- X. **NADIR GÖRÜLEN İPILIMUMAB TOKSISITESİ: ERITEMA NODOSUM**
YAŞAR H. A., ÖZYURT N., UTKAN G.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, pp.341
- XI. **TIROZIN KINAZ İNHIBİTÖRÜ İLE TEDAVİ EDİLEN METASTATİK RENAL HÜCRELİ KANSER OLGULARINDA SİSTEMİK İMMÜN İNFLAMASYON İNDEKSİNİN TEDAVİ YANITI İLE İLİŞKİSİ**
BİR YÜCEL K., YAŞAR H. A., UÇAR G., UTKAN G., ÖZDEMİR N., ÜRÜN Y.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, pp.177
- XII. **Metastatik Pankreas Kanserinde 2. Basamak Tedavilerin Etkinliği**
ŞENDUR M. A. N., BİLGİN B., KARCI GÜNER E., ERGÜN Y., ESİN E., KÖKSOY E. B., SEZER A., ÖZDEMİR N., ÇAKMAK ÖKSÜZOĞLU Ö. B., YALÇIN B., et al.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018
- XIII. **SUNITINIB VE ZOLEDRONIK ASIT KULLANIMI İLE GELİŞEN ÇENE OSTEONEKROZU VAKASI**
KUBİLAY TOLUNAY P., YAŞAR H. A., ÜRÜN Y., UTKAN G.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, pp.287
- XIV. **SYSTEMIC IMMUNE INFLAMMATION INDEX AND TREATMENT RESPONSE IN PATIENTS WITH METASTATIC RENAL CELL CANCER**
BİR YÜCEL K., YAŞAR H. A., UÇAR G., UTKAN G., ÖZDEMİR N., ÜRÜN Y.
2018 GENITOURINARY CANCERS SYMPOSIUM, SAN-FRANCISCO,CALIFORNIA, United States Of America, 8 - 10 February 2018, vol.36, pp.591
- XV. **Systemic immune inflammation index and treatment response in patients with metastatic renal cell cancer.**
Yacel K. B., Yasar A., Ucar G., Utkan G., Yildirim N., ÜRÜN Y.
Genitourinary Cancers Symposium, San-Francisco, Costa Rica, 8 - 10 February 2018, vol.36
- XVI. **Relationship between metabolic parameters and ras mutation status**
KARCI E., SOYDAL Ç., UTKAN G., ÜRÜN Y., AKBULUT H.
30th Annual Congress of the European Association of Nuclear Medicine, 21 - 25 October 2017, vol.44, pp.696
- XVII. **A single center analysis of evolving experience with ALPPS procedure: Towards better patient and graft selection**
BALCI D., KIRIMKER E. O., ÖZÇELİK M., ÜSTÜNER E., KONCA C., UTKAN G., AKBULUT H., ÜRÜN Y., ÇAY ŞENLER F.,

- DEMİRKAZIK A., et al.
12th Biennial E-AHPBA Congress 2017, Mainz, Germany, 23 - 26 May 2017
- XVIII. **Kalp ve Beyin Metastatik Yassı Hücreli Dil Karsinomu Olgusu**
ÜRÜN M., ÖZYURT N., KÖKSOY E. B., YAŞAR H. A., KARCI E., UTKAN G., AKBULUT H.
22. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2017, pp.321
- XIX. **Onkoloji pratığında aşılama ve etkileyen faktörler**
ALKAN A., karcı E., YAŞAR H. A., Tuncay G., KÖKSOY E. B., Ürün M., ÇAY ŞENLER F., DEMİRKAZIK A., UTKAN G., AKBULUT H., et al.
22. Ulusal Kanser Kongresi, Turkey, 19 - 23 April 2017
- XX. **Metastatik Olmayan Kolorektal Adenokanserlerde Lenf Nodu Metastazı İçin Prediktif Faktörlerin Değerlendirilmesi**
KARCI E., KÖKSOY E. B., HOCAZADE C., BİLGİN B., ALKAN A., DEDE İ., TUNCAY G., YAŞAR H. A., ÜRÜN M., ÖZYURT DOĞAN N., et al.
22. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 19 April 2017, pp.242-243
- XXI. **TRPredictive factors of lymph node metastasis in patients with non metastatic colorectal Adenocarcinoma**
Karcı E., KÖKSOY E. B., ALKAN A., Dede İ., Tuncay G., UTKAN G., ÜRÜN Y., AKBULUT H.
ESMO Congress, 7 - 11 October 2016
- XXII. **Vaccination in oncology practice and predictors**
ALKAN A., KARCI E., YAŞAR H. A., TUNCAY G., ÜRÜN M., KÖKSOY E. B., ÜRÜN Y., ÇAY ŞENLER F., UTKAN G., DEMİRKAZIK A., et al.
ESMO, 7 - 10 October 2016
- XXIII. **Medical oncologists attitudes towards vaccination inoncology practice**
ALKAN A., karcı e., YAŞAR H. A., tuncay g., ürün m., KÖKSOY E. B., ÜRÜN Y., ÇAY ŞENLER F., UTKAN G., DEMİRKAZIK A., et al.
ESMO annual meeting, 7 - 11 October 2016
- XXIV. **Nadir bir vaka: Safra kesesi nöroendokrin tümörü**
YAŞAR H. A., ALKAN A., BUDAK B., KÖKSOY E. B., UTKAN G.
6. Türk Tibbi Onkoloji kongresi, Antalya, Turkey, 23 - 27 March 2016, pp.538
- XXV. **Kanser hastasında nadir bir pansitopeni nedeni: Folik asit eksikliği**
YAŞAR H. A., ŞAHİN G., ALKAN A., karcı E., UTKAN G.
6. Türk Tibbi Onkoloji kongresi, Antalya, Turkey, 23 - 27 March 2016, pp.442
- XXVI. **A Rare Cause of Endobronchial Metastasis: Malignant Melanoma**
EROL S., ÇİLEDAĞ A., Karacay E., Kaya A., Ciledag N., KARNAK D., UTKAN G.
CHEST Annual Meeting, Montreal, Canada, 25 - 28 October 2015
- XXVII. **A Rare Cause of Endobronchial Metastasis:Malignant Melanom**
KAYA A., ÇİLEDAĞ A., KARAÇAY E., GÜRÜN KAYA A., ÇİLEDAĞ N., UTKAN G., KARNAK D.
American Thoracic Society Congress 2015, United States Of America, 15 - 20 May 2015
- XXVIII. **The significance of the serum leptin, ghrelin, tumor necrosis factor alpha and interleukine-1 levels in patients with non-small cell lung cancer**
Karatas F., Yalcin B., AKBULUT H., Utkan G., Sahin S., DEMİRKAZIK A., Hacioglu B., Icli F.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXIX. **Sequential use of bevacizumab and cetuximab in patients with K-RAS wild type advanced colorectal cancer.**
AKBULUT H., Gercik O., Icli F., Mizrak D., DEMİRKAZIK A., Onur H., Senler F. C., Utkan G.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXX. **Clinical experience with Vemurafenib in pretreated melanoma (MEL): The results of open label multi**

center study from Turkey

Celik I., Mandel N. M., Gokmen E., Unal O. U., Sevinc A., COŞKUN H. Ş., Buyukberber S., Abali H., Ozguroglu M., Utkan G., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

- XXXI. Associating liver partition with portal vein ligation for staged hepatectomy for gastrointestinal cancer liver metastasis an initial experince with 12 cases**

BALCI D., KONCA C., UZUN Ç., KIRIMKER E. O., ÖZÇELİK M., MEÇO B. C., UTKAN G., GEÇİM İ. E.

11th International Congress of the European-African Hepato-Pancreato-Biliary Association, 21 - 24 April 2015

- XXXII. ALPPS procedure for Colorectal Cancer Liver Metastasis Initial experience with 10 consecutive cases**

BALCI D., KONCA C., UZUN Ç., KIRIMKER E. O., GÖKTUĞ U. U., ÖZÇELİK M., UTKAN G., MEÇO B. C., GEÇİM İ. E.

11th. International Congress of European-African Hepato-Pancreato-Biliary Association, Manchester, United Kingdom, 21 - 24 April 2015

- XXXIII. Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy for Gastrointestinal Cancer Liver Metastasis An Initial Experience with 12 cases**

BALCI D., KONCA C., UZUN Ç., ÖZÇELİK M., UTKAN G., MEÇO B. C., KIRIMKER E. O., GEÇİM İ. E.

International Congress of European-African Hepato-Pancreato-Biliary Association, Manchester, United Kingdom, 21 - 24 April 2015

- XXXIV. Endobronşiyal Metastazın Nadir Bir Nedeni: Malign Melanom**

Karaçay E., Gürün Kaya A., ÇİLEDAĞ A., Çiledağ N., UTKAN G., KAYA A., ÇELİK G., KARNAK D.

Türk Toraks Derneği 18. Yıllık Kongresi, Turkey, 1 - 05 April 2015

- XXXV. Effect of HER2 and hormonal status to FDG uptake on PET CT imaging in recurrent breast cancer**

MIZRAK KAYA D., Onur h., öztürk b., pınar k., UTKAN G., AKBULUT H.

SanAntonio Breast Cancer Conference, 9 - 13 December 2014

- XXXVI. Paklitaksel ilişkili paralitik ileus**

ALKAN A., DUmanlı S., ÖZGÜL S., Mizrak D., UTKAN G.

5.Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014

- XXXVII. Ostogenezis imperfekta, Akalazyva ve gastrik kanser**

Mizrak D., Sungur A. C., ERDOĞDU B., ALKAN A., UTKAN G.

5.Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014

- XXXVIII. Malign Melanomda adjuvant tedavi- Tek merkez deneyimi**

ALKAN A., kuru A., ÖZGÜL S., Mizrak D., UTKAN G.

5.Türk Tıbbi Onkoloji Kongresi, Turkey, 19 March 2014 - 23 March 2020

- XXXIX. Safra kesesi yassı hücreli karsinomda adjuvan tedavi deneyimi**

ALKAN A., ÖZGÜL S., TÜRKELİ M., Mizrak D., SAVAŞ B., UTKAN G.

5.Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014

- XL. Kanser hastalarında bulantı ve etki eden faktörler**

Çelik Ömür S., Özgörgün G., ALKAN A., Mizrak D., UTKAN G.

5.Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014

- XLI. Olgu sunumu: Nadir bir böbrek patolojisi, primer renal anjiyosarkom**

ALKAN A., İdemen C., TÜRKELİ M., Mizrak D., Kuş S., Sertçelik A., UTKAN G.

5.Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014

- XLII. İleri evre Over kanserinde oral melfelan etkinliğinin gösterilmesi**

Mizrak D., ALKAN A., Koçak A., UTKAN G., İÇLİ F.

5.Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014

- XLIII. Olgu Sunumu: Nadir Bir Böbrek Patolojisi, Primer Renal Anjiosarkom**

ALKAN A., İdemen C., Türkeli M., MIZRAK KAYA D., Kuş S., Sertçelik A., UTKAN G.

5. Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014

- XLIV. Otolog Kök Hücre Nakli Sonrası Gelişen Sweet Sendromu**

ALKAN A., İdemen C., SEZER S., MIZRAK KAYA D., Okçu Heper A., UTKAN G.

5. Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014
- XLV. Onkoloji Kliniğinde Yatarak İzlenen Kanser Hastalarında Beslenme Durumu**
Ercan Z., Güven E., Uygun S., ALKAN A., MIZRAK KAYA D., UTKAN G.
5. Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014
- XLVI. Olgu Sunumu: Eozinofili ile Prezente Olan Küçük Hücreli Dışı Akciğer Kanseri**
ALKAN A., İdemen C., Özgül S., MIZRAK KAYA D., UTKAN G.
5. Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014
- XLVII. Paklitaksel İlişkili Paralitik İleus**
ALKAN A., Saraçoğlu P., AKAY HACAN B., MIZRAK KAYA D., UTKAN G.
5. Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014
- XLVIII. Malign Melanomda Adjuvan Tedavi Tek Merkez Deneyimi**
ALKAN A., Kuru A., Özgül S., MIZRAK KAYA D., UTKAN G.
5. Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014
- XLIX. Olgu Sunumu: Kemoembolizasyon İlişkili Mukozal Melanosis**
ALKAN A., Özgül S., SEZER S., İdemen C., MIZRAK KAYA D., UTKAN G.
5. Türk Tıbbi Onkoloji Kongresi, Turkey, 19 - 23 March 2014
- L. Serum CEA and CA 15-3 levels according to breast cancer subtypes**
Dede I., Utkan G., AKBULUT H., ÜRÜN Y., Mizrak D., Icli F.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- LI. Is anemia due to chronic disease the main cause of anemia in cancer patients?**
Utkan G., Kenar G., AKBULUT H., DEMİRKAZIK A., Onur H., Icli F.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- LII. ABO blood group and the risk of breast cancer: Multicenter, case-control, observational study.**
ÜRÜN Y., Koru-Sengul T., Altundag K., Utkan G., Onur H., AKBULUT H., DEMİRKAZIK A., Icli F.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- LIII. ABO blood group and the risk of lung cancer: Multicenter, case-control, observational study**
Utkan G., ÜRÜN Y., Cangir A. K., Oksuzoglu O. B., Ozdemir N., Oztuna D., Kocaman G., DEMİRKAZIK A., Okten I., Icli F.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012
- LIV. The Significance of the Serum Leptin Ghreline Tumor Necrosis Factor Alpha and Interleukine 1 Levels in Patient With Non Small Cell Lung Cancer**
ÜRÜN Y., YALÇIN B., KARATAŞ F., UTKAN G., YÜKSEL C., CANGIR A., ÇAY ŞENLER F., DEMİRKAZIK A., AKBULUT H., İÇLİ F., et al.
The 2011 European Multidisciplinary Cancer Congress. Stockholm, Sweden, Stockholm, Sweden, 24 - 27 September 2011, pp.612
- LV. The role of serum osteopontin (OPN) as a prognostic and predictive marker in patients with advanced gastric cancer.**
YAZICI O., AKBULUT H., Akgün N., UTKAN G., YALÇIN B., İÇLİ F.
ASCO 2011, 2 - 06 June 2011

Metrics

Publication: 165

Citation (WoS): 345

Citation (Scopus): 483

H-Index (WoS): 9

H-Index (Scopus): 12